Sigvotatug - CAS 2764774-90-3

Sigvotatug Vedotin is an antibody-drug conjugate (ADC) designed to selectively target integrin αvβ6-positive tumor cells through an engineered antibody with high specificity. Sigvotatug Vedotin employs a protease-cleavable linker that delivers the cytotoxic payload monomethyl auristatin E (MMAE), a microtubule inhibitor, directly into tumor cells. Upon internalization, MMAE disrupts microtubule organization, inhibits proper cell division, and ultimately results in tumor cell death, providing a targeted strategy in oncology research.

Antibody-Drug Conjugates (ADCs), Integrin

Antibody-drug Conjugate/ADC Related, Cytoskeletal Signaling

2764774-90-3

0.987

-20°C

Ice Packs

Inhibitory Antibodies